Abstract:Obesity has been linked with increased incidence and worse outcomes of at least 13 human cancers. For other cancers, our understanding of their relationship with obesity is more nebulous, with contradictory observations from different studies. An example is lung cancer. Central or visceral obesity is defined as accumulation of excess or abnormal fat in body that is harmful to its health. But in lung cancer, overweight and obesity, as defined by body mass index (BMI), is associated with reduced cancer risk and longer survival after treatment by surgery. In addition, some studies suggest that lung cancer in obese patients responds better to treatment with immune checkpoint inhibitors (ICIs) than in the non-obese. Apart from interesting biological questions, this "obesity paradox" presents practical issues in cancer prevention and clinical management, starting with the fundamental question of whether weight loss should be recommended in these contexts. Our investigations suggest that the incongruence between the observed benefits of obesity and its expected detrimental nature is likely the result of two main confounding factors in lung cancer studies. The first major confounding factor which we noticed is that certain commonly used medications have a secondary anti-cancer effect that is obesity-dependent. This is exemplified by the anti-diabetic metformin, which was prescribed 90 million times in 2021 in the US. We found that metformin use was associated with decreased likelihood of recurrence of early-stage lung cancer after resection, but only in overweight/obese patients (BMI > 25). Additionally, in late-stage cancer, metformin use by such patients correlated with a decrease in immune checkpoint molecules in their tumors, whereas an opposite effect of metformin use was seen in patients with lower BMI ( 90% of lung cancer. A retrospective analysis of more than 500 such patients who were treated with ICIs in our institution showed that this is indeed the case. Consistent with our mouse studies, disease progression among the ICI-treated patients was slowed by metformin in only overweight/obese patients. This set of observations raises the possibility that obesity-dependent anti-cancer effects similar to metformin's may exist for other commonly used drugs, especially those impacting cellular metabolism. Indeed, we found this to be the case for statins. In one study of approximately 600 early-stage non-small cell lung cancer patients who had resective surgery at our institution, use of statins was associated with longer recurrence-free survival in overweight/obese but not other patients. Our observations on confounding by metformin and statins show that the use of such medications has to be accounted for if the effect of obesity on cancer behavior is to be estimated in clinical or epidemiological studies. The other major confounding factor is the use of BMI as a measure of obesity. The validity of BMI as a sole measure of obesity is increasingly being questioned because it does not accurately capture body fat content or its heterogeneity and distribution, which are also biologically relevant. We find this to be the case in lung cancer as well. In a case-control study for which we used routine computerized tomographic (CT) images to accurately measure the body's fat content, we found that patients with early-stage lung cancer have more fat, but not higher BMI, than subjects without lung cancer but at high risk for the disease. Correspondingly, in mice, we and others have found that diet-induced obesity increases lung carcinogenesis by urethane and oncogenic Kras. This accelerated tumor growth is accompanied by enhanced suppressor leukocyte pools in the lung. To test if compromised immune surveillance could underpin the increased risk of cancer seen in obese patients, we characterized the leukocytes recovered from bronchoalveolar lavage fluids of subjects determined obese and non-obese by CT image analysis. Consistent with our hypothesis, and with our assessment of the lung immune cells of obese and non-obese mice, obese subject -Abstract Truncated-

Abstract 4427: Do changes in lipid metabolism link obesity to pancreatic cancer

Abstract A057: Decreased plasma linoleic acid and increased oleic acid associated with obesity in pancreatic cancer

Abstract 3427: Serum metabolites and pancreatic ductal adenocarcinoma in two prospective cohorts

Abstract B048: Targeting PPARG to block obesity-associated pancreatic cancer progression

Abstract C050: Elucidating mechanisms of endocrine-exocrine signaling in obesity-driven pancreatic cancer

Abstract C048: Obesity transforms the gut microbiome to invoke a cancer permissive state

Abstract IA16: Feeding the flames of pancreatic cancer

Abstract 2179: Microbiome-derived metabolites mediate carcinogenic alterations of breast tissue in the context of obesity

Abstract 3406: Transcriptomic analysis reveals differentially expressed pathways in colon tumors of cancer patients with vs without obesity: Results from the ColoCare Study

Abstract 2190: Transcriptomic signatures of obesity-driven colon cancer: A multi-species transdisciplinary approach

Abstract C103: Differential acquisition of extracellular lipid correlates with pancreatic cancer subtype and metastatic tropism

1652P Interaction between enhanced cytokine signalling and ferroptosis defence fuels obesity-associated pancreatic ductal adenocarcinoma oncogenesis

Abstract B049: Pancreatic beta cell stress pathways drive pancreatic ductal adenocarcinoma development in obesity

Abstract 6818: Obesity-mediated perineural invasion promotes PDAC tumorigenesis

Abstract 3682: Pre-surgical blood metabolites associated with ovarian cancer prognosis

Abstract 3846: The obesity paradox in immune checkpoint blockade: A pan-tumor analysis

Abstract A029: Metabolomic profiles among African-American and White breast cancer survivors: An exploratory comparison of correlations with body weight and body composition

Abstract 3377: Exploring the role of obesity-induced exosome secretion and associated proteins in endometrial cancer pathogenesis: A roadmap for prevention through exosome inhibition

Abstract SY38-02: Clinical investigations of obesity in cancer: BMI and other confounders

Abstract B053: Physical activity regulates targetable transcriptomic changes in the adipose tissue of obese PDAC mice

Abstract 3935: Involvement of nanoscale physical communication in obesity-associated breast cancer severity